Cipla Limited

Cipla Limited (India) holds 166 active US FDA Type II Drug Master Files and 119 inactive, has DMF or CEP filings on record for 40 active ingredients, holds 2 active Type IV (excipient) Drug Master Files and is linked to 6 FDA-registered manufacturing sites. 50 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Cipla Limited: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/cipla-limited

Overview

Cipla Limited is a global pharmaceutical company based in India focused on developing, manufacturing, and distributing a wide range of medications. The company specializes in therapies for various medical conditions, ensuring access to affordable medicines for patients worldwide.

Core services & business areas

ManufacturingRegulatory AffairsResearch and DevelopmentSupply Chain

Therapeutic areas

Active ingredients with DMF or CEP filings

Substances for which Cipla Limited holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

Cipla Limited holds 166 active (285 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • TROFINETIDE (C)Active2026-08-19
  • TERLIPRESSIN ACETATEActive2026-04-15
  • RESMETIROM (C)Active2026-03-26
  • TROFINETIDEActive2026-03-21
  • RIBOCICLIB SUCCINATEActive2026-03-18
  • UMECLIDINIUM BROMIDEActive2026-03-12
  • ZAVEGEPANT HYDROCHLORIDEActive2026-03-06
  • ETRASIMOD ARGININEActive2026-03-03
  • LENACAPAVIR SODIUMActive2026-02-03
  • ENSIFENTRINE (C)Active2025-11-26
  • CALCIUM GLUCONATE MONOHYDRATE USPActive2025-11-25
  • ABEMACICLIBActive2025-10-31
  • GLYCOPYRROLATE USPActive2025-09-30
  • IXAZOMIB CITRATEActive2025-08-13
  • DIBASIC POTASSIUM PHOSPHATE USPActive2025-08-10
  • DEUCRAVACITINIBActive2025-03-28
  • MONOBASIC POTASSIUM PHOSPHATE NFActive2025-03-28
  • MOMETASONE FUROATE USPActive2025-03-28
  • ENSIFENTRINEActive2025-03-25
  • NIRAPARIB TOSYLATE MONOHYDRATEActive2025-03-21
  • RESMETIROMActive2025-02-28
  • DAPRODUSTATActive2025-01-31
  • DARUNAVIR HYDRATE (PROCESS II)Active2025-01-10
  • OMEPRAZOLE USP PROCESS-IIActive2024-12-31
  • APIXABANActive2024-12-30
  • RELUGOLIXActive2024-03-29
  • IVACAFTORActive2024-02-16
  • VILANTEROL TRIFENATATEActive2024-02-11
  • POMALIDOMIDEActive2023-12-20
  • ISAVUCONAZONIUM SULFATEActive2023-12-18
  • DASATINIB MONOHYDRATEActive2023-11-30
  • ESCITALOPRAM OXALATE USP (PROCESS-II)Active2023-10-12
  • BREXPIPRAZOLEActive2023-07-20
  • ACALABRUTINIB MALEATEActive2023-07-14
  • RUXOLITINIB PHOSPHATEActive2023-07-13
  • CITALOPRAM HYDROBROMIDE USPActive2023-03-29
  • CABOTEGRAVIRActive2023-03-20
  • RILPIVIRINEActive2023-03-16
  • SORAFENIB TOSYLATE USPActive2023-02-28
  • CABOTEGRAVIR SODIUMActive2023-02-27
  • DIFELIKEFALIN ACETATEActive2023-01-25
  • NIRMATRELVIRActive2023-01-18
  • ABIRATERONE ACETATE USPActive2023-01-14
  • TAFAMIDIS (I)Active2022-12-28
  • TAFAMIDISActive2022-11-28
  • SIPONIMOD ADIPIC ACIDActive2022-11-17
  • TENOFOVIR ALAFENAMIDE MONOFUMARATEActive2022-09-27
  • OLAPARIBActive2022-08-01
  • INDACATEROL ACETATEActive2022-05-13
  • REVEFENACINActive2022-05-06

Showing the 50 most relevant of 285 Drug Master Files (active first). The full list is in the FDA DMF list.

Excipient Drug Master Files

Cipla Limited holds 2 active (2 total) FDA Type IV Drug Master Files. A Type IV DMF covers an excipient, colourant or flavour, not an active ingredient; these are counted separately from the API filings above.

Registered manufacturing sites (6)

Physical sites registered with the US FDA and resolved to Cipla Limited, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

50 FDA enforcement records linked to this company.

  • recall — Class II2025-12-10

    Failed Stability Specifications: Observed OOS results: eg results for colour index

  • 4832024-06-21

    Computer control of master formula records

  • 4832024-06-21

    Investigations of discrepancies, failures

  • 4832024-06-21

    Environmental Monitoring System

  • 4832024-06-21

    Test methods

  • 4832024-06-21

    Procedures not in writing, fully followed

  • 4832024-06-21

    Cleaning System

  • warning_letter2023-11-17

    FDA Warning Letter (drug product)

  • recall — Class II2022-10-12

    Lack of Assurance of Sterility: environmental monitoring failure.

  • recall — Class II2022-10-05

    Lack of Assurance of Sterility

  • recall — Class II2022-09-14

    Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility.

  • recall — Class II2022-09-14

    Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility.

  • 4832022-08-26

    Procedures not in writing, fully followed

  • 4832022-08-26

    Cleaning System

  • 4832022-08-26

    Environmental Monitoring System

  • 4832022-08-26

    Cleaning SOPs/schedules

  • 4832022-08-26

    Validation lacking for sterile drug products

  • 4832022-08-26

    Computer control of master formula records

  • recall — Class II2022-08-17

    Lack of Assurance of Sterility: Complaints received of defective container closure.

  • recall — Class II2022-07-27

    Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility.

  • recall — Class II2021-07-21

    CGMP Deviations

  • recall — Class II2021-01-06

    Cross- contamination with other products: The excipient, Crospovidone, NF is contaminated with theophylline

  • recall — Class II2021-01-06

    Cross- contamination with other products: The excipient, Crospovidone, NF is contaminated with theophylline

  • recall — Class II2021-01-06

    Cross- contamination with other products: The excipient, Crospovidone, NF is contaminated with theophylline

  • recall — Class II2020-12-23

    cGMP deviations: Vials may not be sealed correctly affecting sterility.

  • warning_letter2020-02-12

    FDA Warning Letter (drug product)

  • 4832019-09-27

    Investigations of discrepancies, failures

  • 4832019-09-27

    Absence of Written Procedures

  • 4832019-09-27

    Equipment Design, Size and Location

  • 4832019-09-27

    Equipment to control conditions

  • 4832019-09-27

    Validation lacking for sterile drug products

  • 4832019-09-27

    Equipment for Environmental Control

  • 4832019-09-27

    Approval and review of procedures

  • 4832019-09-27

    Procedures for sterile drug products

  • 4832019-09-27

    Buildings of Suitable Size, Construction, Location

  • 4832019-09-27

    Sampling/testing of in-process materials

  • 4832019-09-27

    Cleaning / Sanitizing / Maintenance

  • 4832019-09-27

    Written procedures not established/followed

  • recall — Class II2018-12-26

    Failed Dissolution Specifications.

  • 4832017-12-06

    Results of drug product inspections and examinations

  • 4832017-12-06

    Extent of discrepancy, failure investigations

  • 4832017-12-06

    Investigations of discrepancies, failures

  • 4832017-12-06

    Procedures not in writing, fully followed

  • 4832017-12-06

    Written program not followed

  • 4832017-12-06

    Complaint Handling Procedure

  • 4832017-12-06

    Training , Education , Experience overall

  • 4832017-12-06

    Following/documenting laboratory controls

  • 4832017-12-06

    SOPs not followed / documented

  • recall — Class III2015-05-20

    Failed Impurities/Degradation Specifications: Product is out of specification for a known degradant.

  • 4832014-06-25

    Timely submission

For suppliers

Is this Cipla Limited?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.